Follow us on Twitter
twitter icon@FreshPatents


Gastrointestinal Disease patents

      

This page is updated frequently with new Gastrointestinal Disease-related patent applications.




 Method to predict or diagnose a gastointestinal disorder or disease patent thumbnailMethod to predict or diagnose a gastointestinal disorder or disease
The disclosure provides methods and compositions useful for identifying a subject's predisposition to a gastrointestinal disease or disorder.. .

 Substituted prolines / piperidines as orexin receptor antagonists patent thumbnailSubstituted prolines / piperidines as orexin receptor antagonists
The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as ox1 or ox2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. For example, orexin receptor-modulatory compounds of the present invention can be used in treatment of an eating disorder, obesity, alcoholism or an alcohol-related disorder, drug abuse or addiction including addiction to cocaine, opiates, amphetamines, or nicotine, a sleep disorder, a cognitive dysfunction in a psychiatric or neurologic disorder, depression, anxiety, panic disorder, schizophrenia, alzheimer's disease, parkinson's disease, huntington's chorea, headache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases, cancer, hypertension, behavior disorder, mood disorder, manic depression, dementia, sex disorder, psychosexual disorder, or renal disease..
Eolas Therapeutics, Inc.


 Antibodies that specifically bind to tl1a patent thumbnailAntibodies that specifically bind to tl1a
Recombinantly expressed variant antibodies that have enhanced affinity for tl1a and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between tl1a and the death receptor 3 (dr3).
Cephalon, Inc.


 Suprametallogels and uses thereof patent thumbnailSuprametallogels and uses thereof
The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., pd(ii)-, ni(ii)-, or fe(ii)-ligand of formula (a)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers y.
Massachusetts Institute Of Technology


 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders patent thumbnailAgonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
The invention provides novel guanylate cyclase-c agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cgmp-dependent phosphodiesterase.
Synergy Pharmaceuticals, Inc.


 Piperidine compounds, pharmaceutical composition comprising the same and its use patent thumbnailPiperidine compounds, pharmaceutical composition comprising the same and its use
Piperidine compounds and pharmaceutically useful salts thereof, a pharmaceutical composition including an effective amount of the racemic or enantiomerically enriched piperidine compounds to treat gastrointestinal diseases, and a method of treating gastrointestinal diseases in a mammal are provided.. .
Sk Biopharmaceuticals Co., Ltd.


 Somatic stem cells patent thumbnailSomatic stem cells
Described herein is a method of treating a disorder, the method comprising: administering to a subject in need thereof a composition that contains a population of somatic stem cells that are 0.3-6.0 micrometers in size and cd9+, cd349+, cd133−, cd90−, cd34−, ssea1+, ssea4+, cd13+, or stro1+, wherein the disorder is selected from the group consisting of a neurodegenerative disease, nervous system disorder, cancer, metabolic disorder, autoimmune disorder, inflammatory disorder, heart or circulatory disorder, blood disorder, muscular dystrophy, gastrointestinal disease, kidney disease, liver disease, lung disease, adrenal disorder, a condition resulting from an injury, a condition associated with aging, and virus infection.. .
Stembios Technologies, Inc.


 Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders patent thumbnailAgonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
The invention provides novel guanylate cyclase-c agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cgmp-dependent phosphodiesterase.
Synergy Pharmaceuticals, Inc.


 Fluorinated arylalkylaminocarboxamide derivatives patent thumbnailFluorinated arylalkylaminocarboxamide derivatives
Fluorinated arylalkylaminocarboxamide derivatives of formula (i) are described wherein w, j, n, r1, r2, r2′, r3, r4, r5 and r6 have the meanings as defined in the specification and pharmaceutically salts thereof, pharmaceutical compositions containing them as active ingredients and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including neurological, psychiatric, cardiovascular, inflammatory, ophthalmic, urolological, and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.. .
Newron Pharmaceuticals S.p.a.


 Use and identification of biomarkers for gastrointestinal diseases patent thumbnailUse and identification of biomarkers for gastrointestinal diseases
The described invention relates to the identification of biomarkers for gastrointestinal diseases and provides methods utilizing the biomarkers for in drug discovery, monitoring of treatment efficacy, and diagnostics. The invention further provides methods for identifying a therapeutic target to treat ulcerative colitis, colorectal cancer, and crohn's disease..
Alfagene Bioscience, Inc.


Drug for disease caused by expression of periostin except eye disease, and use thereof

The present invention is intended to provide a novel molecule that inhibits the expression of the periostin gene that is effective in treatment of diseases caused by the expression of periostin except for eye diseases. A drug for a disease caused by the expression of periostin except for an eye disease includes, as an expression inhibitory sequence for the periostin gene, a nucleic acid molecule including a nucleotide that has a base sequence represented by any one of seq id nos: 1 to 19.
Aqua Therapeutics Co., Ltd.

Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases

Wherein d, x, y, r1, r2, r3, r4, r5, r6, r7 and r8 are as defined herein.. .

Quinine compounds, and optical isomers, preparation method and medical use thereof

The present invention discloses a class of quinine compounds and pharmaceutically acceptable salts, solvates, prodrugs or optical isomers thereof. Also disclosed in the present invention are that the above compounds have a selective antagonistic effect on the receptor subtypes of m1 and m3, but have no significant effect on m2 receptor subtype, and the above compounds are characterized by rapid action, long-lasting efficacy, and low toxic and side-effects when used to treat rhinitis, post-cold rhinitis, chronic trachitis, airway hyperresponsiveness, asthma, chronic obstructive pulmonary diseases, cough, urinary incontinence, frequent urination, unstable bladder syndrome, bladder spasms, bladder inflammation and gastrointestinal diseases such as irritable bowel syndrome, spastic colitis, as well as duodenal and gastric ulcers..
Beijing Fswelcome Technology Development Co., Ltd

Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders

The invention provides novel guanylate cyclase-c agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cgmp-dependent phosphodiesterase.
Synergy Pharmaceuticals, Inc.

Compositions and methods for treatment and prophylaxis of gastrointestinal diseases

Methods and compositions for treating inflammatory bowel disease, irritable bowel syndrome, and travelers' diarrhea involve the use of targeted antibiotics in combination with probiotic formulations. The probiotics mitigate many of the deleterious side effects associated with antibiotic use and permit the antibiotic to be administered at a higher dose and for a longer duration than would otherwise be possible in the absence of the probiotic.

Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders

The invention provides novel guanylate cyclase-c agonist peptides and their use in the treatment of human diseases including gastrointestinal disorder, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cgmp-dependent phosphodiesterase.
Synergy Pharmaceuticals, Inc.

Compositions and methods

Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.. .
Seres Therapeutics, Inc.

Compositions and methods

Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.. .

Multi-tailed lipids and uses thereof

The present invention provides multi-tailed lipid compounds, and salts and stereoisomers thereof, and methods of preparing the compounds. Also provided are compositions including a compound of the invention and an agent (e.g., an sirna, mrna, plasmid dna, small molecule, protein, peptide).
Massachusetts Institute Of Technology

Compositions and methods

Provided are defined bacterial compositions for the maintenance or restoration of a healthy microbiota in the gastrointestinal tract of a mammalian subject, and methods for populating the gastrointestinal tract of a subject. Provided also are bacterial formulations for oral or gastric administration to a mammalian subject in an effective amount for prevention or treatment of a gastrointestinal disease, disorder or condition..
Seres Therapeutics, Inc.

Composition for preventing and treating gastrointestinal diseases, containing essential oils extracted from litsea japonica fruit

The present invention relates to a composition for preventing and treating gastrointestinal diseases by using litsea japonica, and specifically, to a composition for preventing and treating gastrointestinal diseases, containing essential oils extracted from litsea japonica fruit as an active ingredient. According to the present invention, the essential oils extracted from litsea japonica fruits (pure fruit, seed fruit, and seeds) and used as the active ingredient of the composition for preventing and treating gastrointestinal diseases have been confirmed to have excellent effects in an efficacy evaluation for relieving gastrointestinal diseases caused by helicobacter pylori, which is a gastrointestinal disease factor, physical factors induced by stress, and chemical factors induced by indomethacin.
Jeju Technopark

Compositions and methods for the treatment of inflammatory bowel disease

The invention relates to the compounds of formula i and formula ii or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i or formula ii; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
Cellix Bio Private Limited

Compositions and methods for the treatment of inflammatory bowel disease

The invention relates to the compounds of formula i and formula ii or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i or formula ii; and methods for treating or preventing inflammatory bowel disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

Bicyclic derivative containing pyrimidine ring, and preparation method therefor

The present invention provides: a bicyclic derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof; a preparation method therefor, a pharmaceutical composition comprising the same; and a use therefor. According to the present invention, the bicyclic compound derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof acts as a 5-ht4 receptor agonist, and thus can be usefully applied to the prevention or treatment of dysfunction in gastrointestinal motility, for example, gastrointestinal diseases such as gastroesophageal reflux disease (gerd), constipation, irritable bowel syndrome (ibs), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, diabetic gastric atony and the like..
Yuhan Corporation

Antibodies against clostridium difficile toxins and methods of using the same

Monoclonal antibodies or antigen-binding fragments thereof that bind to clostridium difficile (c. Difficile) toxin a or toxin b and methods of using the same to detect or treat c.
Sanofi Pasteur Biologics, Llc

Brush-poly (glycoamidoamine)-lipids and uses thereof

Which may assist the pgal and/or a complex of the pgal and an agent to pass through cell membranes or be taken up by cells. Also provided are compositions including a described pgal and an agent (e.g., polynucleotide, small molecule, peptide, or protein).

Compositions and methods for binding cysteinyl leukotrienes (cyslts) for treatment of disease

Methods are provided for using antibodies and antibody fragments that bind one or more cysteinyl leukotrienes (cyslts) for treatment of diseases, including inflammatory, respiratory and gastrointestinal diseases and conditions associated with aberrant levels of one or more cyslts. Anti-cyslt antibodies and antigen-binding antibody fragments, and compositions containing such antibodies and antibody fragments, are also provided..
Lpath, Inc.

Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation

The present invention provides a use of a lipid composition for the preparation of a nutritional, pharmaceutical or nutraceutical composition or a functional food, for the prevention and treatment of gastrointestinal diseases and disorders, and for promoting intestinal development, maturation, adaptation and differentiation.. .
Enzymotec Ltd.

Methods, compounds, and compositions for the treatment of angiotensin-related diseases

Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer.. .
University Of Southern California

Polyamine-fatty acid derived lipidoids and uses thereof

The present disclosure provides polyamine-fatty acid derived lipidoids (e.g., compounds of formula (i) or (ii)) and methods of preparing the lipidoids. A described lipidoid includes r—c(═o)—o— moieties (where r is a lipid moiety), which may be hydrolyzed into non-toxic fatty acids.
Massachusetts Institute Of Technology

Hydroxyindalpine derivatives and their medical use

The present invention relates to hydroxyindalpine derivatives of formula (i) as defined herein and pharmaceutical compositions comprising these compounds, as well as their medical use, particularly in the treatment or prevention of gastrointestinal diseases/disorders, such as constipation and functional dyspepsia.. .
Technische UniversitÄt MÜnchen



Gastrointestinal Disease topics:
  • Gastrointestinal Disease
  • Gastrointestinal
  • Gastrointestinal Diseases
  • Intestinal Diseases
  • Inflammation
  • Pharmaceutically Acceptable Salt
  • Inflammatory Bowel Disease
  • Bowel Disease
  • Constipation
  • Irritable Bowel Syndrome
  • Human Diseases
  • Gastrointestinal Disorders
  • Ulcerative Colitis
  • Gastrointestinal Cancer
  • Human Disease


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Gastrointestinal Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Gastrointestinal Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.3257

    file did exist - 3138

    2 - 1 - 52